Course: Clarifying the Risks and Benefits of JAKI in RA
CME Credits: 1.00
Released: 2024-12-18
The treatment landscape for rheumatoid arthritis (RA) changed after clinical trials showed that treatment outcomes for Janus kinase (JAK) inhibitors were comparable and, in some cases, superior to those of biologics. But JAK inhibitors have also been associated with serious adverse events, including major adverse cardiac events (MACE), malignancies, thrombosis, and infections, which are identified in a boxed warning on their FDA-approved labelling. Thus, clinicians must stay up to date with the latest JAK inhibitor safety and efficacy data, and understand how and when to use these agents to manage patients with RA while ensuring safety. Join a panel of rheumatologists to explore the critical role played by the JAK-STAT pathway in the pathophysiology of RA. Panelists will review JAK inhibitor efficacy and safety data, including cardiovascular, thrombotic, malignancy, and infection risks. Real-life experiences with JAKi and key trial results will be shared and discussed.
View Full Course